Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients


We evaluated the safety and efficacy of intrapericardial bevacizumab (BEV) for treating symptomatic malignant pericardiac effusion (MPCE) in seven advanced cancer patients. All patients had previously undergone multiple lines of systemic therapy. Each patient received paracentesis and intrapericardial infusions of 100 or 200 mg of BEV every two weeks… (More)
DOI: 10.18632/oncotarget.9420


5 Figures and Tables

Slides referencing similar topics